Bloodstream Infection Testing Market properties, sharing analysis and overview
Bloodstream Infection Testing Market Overview :
Bloodstream infections (BSIs) are serious medical conditions
that occur when microorganisms, such as bacteria or fungi, enter the
bloodstream. Prompt and accurate diagnosis of BSIs is crucial for effective treatment
and patient outcomes. Bloodstream infection testing is a critical component of
diagnosing these infections.
The Bloodstream
Infection Testing market encompasses a range of diagnostic tests used to
identify the causative microorganisms and determine antimicrobial
susceptibility. These tests are essential for guiding appropriate antimicrobial
therapy and preventing the spread of infections.
Key Restraints:
Several factors can restrain the growth of the Bloodstream
Infection Testing market:
·
High Cost of Testing: Advanced diagnostic tests,
such as molecular diagnostics, can be expensive, limiting their accessibility
in certain healthcare settings, particularly in low- and middle-income
countries.
·
Complex Laboratory Procedures: Some tests
require specialized laboratory equipment and skilled personnel, which can be
challenging to implement in resource-limited settings.
·
Emergence of Antimicrobial Resistance: The
increasing prevalence of antimicrobial-resistant microorganisms can complicate
the diagnosis and treatment of BSIs, necessitating more advanced testing
methods.
·
The high cost of ownership and maintenance of
devices is the restraining factor for the bloodstream
infection testing market growth. Automated devices required for both
conventional and advanced bloodstream infection tests such as PCR machines, and
MALDI- TOF analysers are equipped with several advanced features and functions.
·
The high cost of instruments, consumables, and labour
significantly affects end-user industries. Diagnostic laboratories and research
industries require multiple such systems and hence capital cost increases
ominously.
·
On the other hand, research institutes run on
limited funds, so they cannot afford such systems.
·
Diagnostic laboratories and research industries
require multiple such systems and hence capital cost increases ominously. On
the other hand, research institutes run on limited funds, so they cannot afford
such systems.
Future Opportunities:
Despite these challenges, several opportunities exist for
the growth of the Bloodstream Infection Testing market:
·
Rising Prevalence of Bloodstream Infections: The
increasing incidence of healthcare-associated infections and immunocompromised
populations can drive demand for rapid and accurate diagnostic tests.
·
Advancements in Diagnostic Technologies: The
development of innovative technologies, such as rapid diagnostic tests and
molecular diagnostics, can improve the speed and accuracy of BSI diagnosis.
·
Increased Focus on Antimicrobial Stewardship:
Efforts to optimize antimicrobial use can lead to increased demand for diagnostic
tests to guide appropriate therapy and prevent the emergence of resistance.
·
Extensive research activities have created ample
space for the development and growth of the bloodstream infection testing
market opportunities. Technological advancement such as next-generation
sequencing of microbial cell-free DNA (mcfDNA-seq) is expected to emerge as a
promising diagnostic method for bloodstream infection.
·
In February 2020, in the United Kingdom, the
National Institute for Health and Care Excellence (NICE) issued guidance
recommending the use of rapid bloodstream infection testing in certain
settings, such as emergency departments and intensive care units.
·
Health and Care Excellence (NICE) issued
guidance recommending the use of rapid bloodstream infection testing in certain
settings, such as emergency departments and intensive care units.
·
The analysis of trends
in the market concludes that the growing government initiatives for
healthcare research and development activities are emerging as one of many
bloodstream infection testing market opportunities that will drive market
expansion across the globe over the forecast period.
Segmentation :
The Bloodstream Infection Testing market can be segmented
based on various factors:
Product Type:
·
Consumables
·
Instruments
·
Software
End-User:
·
Hospitals
·
Diagnostic Centers
·
Research Institutes
·
Others
Regional Analysis :
The Bloodstream Infection Testing market is expected to
witness significant growth in various regions, including:
·
North America: This region is a major market for
BSI testing due to the high prevalence of healthcare-associated infections and
advanced healthcare infrastructure.
·
Europe: This region is characterized by a strong
focus on healthcare quality and patient safety, driving demand for accurate and
rapid diagnostic tests.
·
In 2022, North America accounted for the highest
market share at 38.25% valued at USD 1,255.99 Million in 2022 and USD 1,307.85
Million in 2023, it is expected to reach USD 1,864.86 Million in 2031.
·
The Centers for Disease Control and Prevention
(CDC) in September 2021, at least 1.7 million adults in the U.S. develop sepsis
each year which leads to 270,000 every year. Furthermore, according to the
report by the National Institute of Health in November 2022
·
Asia-Pacific: This region is experiencing rapid
growth in the healthcare sector, particularly in emerging economies like China
and India, leading to increased demand for BSI testing.
Recent Developments :
The Bloodstream Infection Testing market is continuously
evolving with recent developments such as:
·
Development of Rapid Diagnostic Tests: The
development of rapid diagnostic tests, such as lateral flow immunoassays and
polymerase chain reaction (PCR) tests, can provide timely results and guide
immediate treatment decisions.
·
Integration of Artificial Intelligence: The
integration of AI-powered tools can improve the accuracy and efficiency of BSI
diagnosis by analyzing complex data and identifying patterns.
·
In April 2020, Thermo Fisher Scientific
announced a collaboration with NanoPin Technologies, Inc. to develop a highly
sensitive analytical workflow for infectious disease diagnosis and patient
monitoring. The collaboration aims to improve blood-based infectious disease
detection technology.
·
In December 2021, Roche launched the first
infectious disease tests on the Cobas 5800 System in countries accepting the CE
mark for blood testing. The Cobas 5800 System is a compact, fully automated
molecular system that helps address the lab requirements. The tests are
designed to support patient management of human immunodeficiency virus,
Hepatitis B and C virus.
Contact us:
Consegic
Business intelligence Pvt Ltd.
Contact no: (US) (505) 715-4344
Email: sales@consegicbusinessintelligence.com
Other Reports;
Comments
Post a Comment